Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To compare pemetrexed plus enzastaurin when given in a twice daily dosing schedule versus pemetrexed plus placebo twice daily in terms of the progression-free survival time (PFS) of patients receiving second-line therapy for the treatment of locally advanced or metastatic NSCLC.
Critère d'inclusion
- Advanced or Metastatic Non Small Cell Lung Cancer